Ocular hypotensive effect and safety of brinzolamide opthalmic solution in open angle glaucoma patients

Journal of the Formosan Medical Association

Volumn 103, Issue 5, 2004, Pages 369-373

  Wang, Tsing Hong ^a   Huang, Jehn Yu ^a   Hung, Por T ^a   Shieh, Jui Wen ^a   Chen, Yuh Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Brinzolamide; Glaucoma; Open angle; Randomized controlled studies; Timolol

Indexed keywords

BRINZOLAMIDE; EYE DROPS; TIMOLOL MALEATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; SULFONAMIDE; THIAZINE DERIVATIVE; TIMOLOL;

ADULT; ARTICLE; BIOMICROSCOPY; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA THICKNESS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; EXPERIMENTAL DESIGN; EYE IRRITATION; EYE PAIN; EYE REDNESS; EYE REFRACTION; FEMALE; FOLLOW UP; HEADACHE; HEART RATE; HUMAN; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PACHOMETRY; RANDOMIZED CONTROLLED TRIAL; REFRACTION INDEX; SCREENING TEST; SLIT LAMP; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VISUAL ACUITY; VISUAL IMPAIRMENT; COMPARATIVE STUDY; DRUG EFFECT; SAFETY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; CARBONIC ANHYDRASE INHIBITORS; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; SULFONAMIDES; THIAZINES; TIMOLOL;

EID: 3543051800     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Stamper RL, Lieberman MF, Drake MV: Becker-Shaffer's diagnosis and therapy of the glaucomas. 7th ed. 1999:2.
2. Zimmerman TJ, Kaufman HE: Timolol: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977; 95:601-4.
3. Radius RL, Diamond GR, Pollack IP, et al: Timolol: a new drug for mamagement for chronic simple glaucoma. Arch Ophthalmol 1978;96:1003-8.
4. Steinert RF, Thomas JV, Boerger WP: Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol 1981;99:100-3.
5. Schuman JS: Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. J Am Acad Ophthalmol 2000;107:1171-7.
6. Hurvitz LM, Kaufman PL, Robin AL: New developments in the drug treatment of glaucoma. Drugs 1991;41:514-32.
7. Michaud JE, Friren B: Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:235-43.
8. De Santis L: Preclinical overview of brinzolamide. Surv Ophthalmol 2000;44:S119-29.
9. Silver LH: Dose-response evaluation of the ocular hypotensive effect of brizolamide ophthalmic suspension. Surv Ophthalmol 2000;44:S147-53.
10. Silver LH: Clinical efficacy and safety of brinzolamide, a new topical carbonic anhydrase inhibitor for primary angel-closure glaucoma and ocular hypertension. Am J Ophthalmol 1998;126:400-8.
11. Wistrand PJ, Schenholm M, Lonnerhol G: Carbonic anhydrase isoenzymes CA I and CA II in the human eye. Invest Ophthalmol Vis Sci 1986;27:419-28.
12. Zimmerman TJ, Kaufman HE: Timolol: dose response and duration of action. Arch Ophthalmol 1977;95:605-7.
13. Katz IM, Berger ET: Effects of iris pigmentation of response of ocular pressure to timolol. Surv Ophthalmol 979;23:395-8.
14. Kuang KY, Xu M, Komiarek JP, et al: Effects of ambient bicarbonate, phosphate, and carbonic anhydrase inhibitors on fluid transport across rabbit corneal epithelium. Exp Eye Res 1990;50:487-93.
15. Wilkerson M, Cyrlin M, Lippa EA, et al: Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993;11:1343-50.
16. Galin MA, Baras I, Zweifach P: Diamox induced myopia. Am J Ophthalmol 1962;54:237-40.
17. Epstein RJ, Allen RC, Lunde MW: Organic impotence associated with carbonic anhydrase inhibitory therapy for glaucoma. Ann Ophthalmol 1987;19:48-50.
18. Lichter PR, Newman CP, Wheeler NC et al: Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol 1978;85:495-502.
19. Wang RF, Serle JB, Podos SM, et al: The effect of MK-927, a topical carbonic anhydrase inhibitor, on IOP in glaucomatous monkeys. Curr Eye Res 1989;9:163-8.
20. Michaud JE, Friren B: The International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:235-43.
21. Adamsons IA, Polis A, Ostrov CS, et al: Dorzolamide Safety Study Group. Two-year safety study of dorzolamide as monotherapy and with timolol pilocarpine. J Glaucoma 1998;7:395-401.
22. March WF, Ochsner KI: The Brizolamide Long-Term Therapy Study Group. The long-term safety and efficacy of brizolamide 1% (AZOPT) in patients with primary open-angle galucoma or ocular hypertension. Am J Ophthalmol 2000;129:136-43.
23. Rouland JF, Le PC, Gouvenia PC, et al: Cost-administration study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Pharmacoeconomics 2003;21:201-13.